Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients
ObjectiveTo evaluate the efficacy and safety of anlotinib-based treatment in metastatic breast cancer (MBC) patients with failure of standard treatment.MethodsWe collected the medical data of 56 female patients with the diagnosis of MBC and had failed the standard treatment before. These patients re...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-12-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1042451/full |
| _version_ | 1797942489853722624 |
|---|---|
| author | Yu Qian Kexin Lou Hao Zhou Lili Zhang Yuan Yuan |
| author_facet | Yu Qian Kexin Lou Hao Zhou Lili Zhang Yuan Yuan |
| author_sort | Yu Qian |
| collection | DOAJ |
| description | ObjectiveTo evaluate the efficacy and safety of anlotinib-based treatment in metastatic breast cancer (MBC) patients with failure of standard treatment.MethodsWe collected the medical data of 56 female patients with the diagnosis of MBC and had failed the standard treatment before. These patients received at least two cycles of anlotinib-based treatment as the second-line or beyond treatment between October 2019 and April 2022 in Jiangsu Cancer Hospital. The primary endpoint of our study was progression-free survival (PFS), and it was estimated with Kaplan-Meier. The second end points were disease control rate (DCR), objective response rate (ORR), and side effects.ResultsThe median PFS time of a total of 56 patients was 5.7 months (95% CI, 3.17-8.23 months). The ORR and DCR was 28.6% and 71.4%, respectively. In second-line, third-line, and beyond treatment, the median PFS was 11.7 months, 8.7 months, and 4.7 months, respectively. In different subtype of breast cancer, the median PFS was 5.6 months, 5.7months, and 6.4 months in human epidermal growth factor receptor 2 positive (HER2+), hormone receptor positive and HER2 negative (HR+/HER2-), and triple negative breast cancer (TNBC) patients, respectively. Most adverse effects were clinically manageable, and the most common events were platelet count decrease (35.7%), hand-foot syndrome (19.6%), diarrhea (19.6%), and fatigue (17.9%). The most common grade 3 and 4 adverse events were platelet count decrease (10.7%), diarrhea (7.1%), and oral mucositis (5.4%).ConclusionAnlotinib-based treatment showed good efficacy and manageable toxicity in multi-line treatment of MBC patients who failed the standard treatment. |
| first_indexed | 2024-04-10T20:08:18Z |
| format | Article |
| id | doaj.art-ad32ae77ff0f447d8392a0be0f5b6676 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-10T20:08:18Z |
| publishDate | 2022-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-ad32ae77ff0f447d8392a0be0f5b66762023-01-26T17:04:11ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-12-011210.3389/fonc.2022.10424511042451Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patientsYu Qian0Kexin Lou1Hao Zhou2Lili Zhang3Yuan Yuan4Department of Oncology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Pathology, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Chemotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Chemotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, ChinaDepartment of Chemotherapy, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, ChinaObjectiveTo evaluate the efficacy and safety of anlotinib-based treatment in metastatic breast cancer (MBC) patients with failure of standard treatment.MethodsWe collected the medical data of 56 female patients with the diagnosis of MBC and had failed the standard treatment before. These patients received at least two cycles of anlotinib-based treatment as the second-line or beyond treatment between October 2019 and April 2022 in Jiangsu Cancer Hospital. The primary endpoint of our study was progression-free survival (PFS), and it was estimated with Kaplan-Meier. The second end points were disease control rate (DCR), objective response rate (ORR), and side effects.ResultsThe median PFS time of a total of 56 patients was 5.7 months (95% CI, 3.17-8.23 months). The ORR and DCR was 28.6% and 71.4%, respectively. In second-line, third-line, and beyond treatment, the median PFS was 11.7 months, 8.7 months, and 4.7 months, respectively. In different subtype of breast cancer, the median PFS was 5.6 months, 5.7months, and 6.4 months in human epidermal growth factor receptor 2 positive (HER2+), hormone receptor positive and HER2 negative (HR+/HER2-), and triple negative breast cancer (TNBC) patients, respectively. Most adverse effects were clinically manageable, and the most common events were platelet count decrease (35.7%), hand-foot syndrome (19.6%), diarrhea (19.6%), and fatigue (17.9%). The most common grade 3 and 4 adverse events were platelet count decrease (10.7%), diarrhea (7.1%), and oral mucositis (5.4%).ConclusionAnlotinib-based treatment showed good efficacy and manageable toxicity in multi-line treatment of MBC patients who failed the standard treatment.https://www.frontiersin.org/articles/10.3389/fonc.2022.1042451/fullmetastatic breast canceranlotinibantiangiogenesisefficacyside effect |
| spellingShingle | Yu Qian Kexin Lou Hao Zhou Lili Zhang Yuan Yuan Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients Frontiers in Oncology metastatic breast cancer anlotinib antiangiogenesis efficacy side effect |
| title | Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients |
| title_full | Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients |
| title_fullStr | Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients |
| title_full_unstemmed | Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients |
| title_short | Efficacy and safety of anlotinib-based treatment in metastatic breast cancer patients |
| title_sort | efficacy and safety of anlotinib based treatment in metastatic breast cancer patients |
| topic | metastatic breast cancer anlotinib antiangiogenesis efficacy side effect |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.1042451/full |
| work_keys_str_mv | AT yuqian efficacyandsafetyofanlotinibbasedtreatmentinmetastaticbreastcancerpatients AT kexinlou efficacyandsafetyofanlotinibbasedtreatmentinmetastaticbreastcancerpatients AT haozhou efficacyandsafetyofanlotinibbasedtreatmentinmetastaticbreastcancerpatients AT lilizhang efficacyandsafetyofanlotinibbasedtreatmentinmetastaticbreastcancerpatients AT yuanyuan efficacyandsafetyofanlotinibbasedtreatmentinmetastaticbreastcancerpatients |